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FK506 (TacrolimuslPrografTh1) is a new immunosup-
pressive agent recently approved by the Food and Drug 
Administration. Although it is formally indicated for use 
only in patients undergoing orthotopic liver transplanta-
tion (1-4), it has been used clinically after transplantation 
of essentially all solid and hollow organs (5-7) and both 
bone marrow (8,9) and pancreatic islets (10). FK506 has 
been used for over 5 years in renal transplant patients, 
both as the primary immunosuppressive agent (11-16) 
and in an attempt to rescue failing kidneys (17). This 
chapter will summarize our clinical experience with adult 
and pediatric renal transplant patients, both in the pri-
mary and rescue setting and will also touch on our series 
of transplants with bone marrow augmentation (18). We 
hope to demonstrate that FK506 is an excellent immu-
nosuppressive agent for patients undergoing renal trans-
plantation and that it represents a formidable addition to 
our armamentarium. 
Early Experience 
The first 2 years' experience with FK506 in renal 
transplant patients included a pilot series, a small ran-
domized trial comparing FK506 with CsA, and a larger 
group of patients not eligible for the randomized trial who 
were given the choice of receiving FK506 or not. The 
latter group included a disproportionately high percent-
age of patients undergoing retransplantation who had 
failed conventional therapy in the past, often at other cen-
ters. These 240 cases were compared with a roughly 
concurrent group of 196 cases managed with conven-
tional CsA-based immunosuppression (19). The patients 
in the randomized trial were also analyzed separately, 
with outcomes similar to the larger group. Comparable 
patient and graft survival rates were seen between FK506 
and CsA-treated patients (Table 1). However, it was pos-
sible for over 40% of the patients on FK506 to be taken 
off prednisone, and antihypertensive medication require-
ments were lower in the FK506 group. In addition, se-
rum cholesterol levels were significantly lower in the 
Table 1. Early experience with FK506 in 
renal transplantation. 
n=240 
Immunosuppression FK506 
1-yr actuarial patient survival 90% 
1-yr actuarial graft survival 74% 
Off steroids 44% 
Off antihypertensive medications 43% 
Cholesterol (mgldl) 
Bp<0.0001 
n=196 
CsA 
94% 
77% 
0% 
25% 
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Table 2. Immunosuppressive protocols- FK5061 
prednisone versus FK506lazathioprinelprednisone. 
FK506-treated patients. The conclusion 
of this early work, during a time when the 
dosing and toxicities were still being evalu-
ated, was that FK506 was certainly as ef-
fective as conventional therapy and might 
even have some advantages with regard 
to secondary issues. 
Immunosuppression 
FK506 Steroids 
Preop 0.15 mglkg po Methylprednisolone IV 
1000 mg 
Postop 0.1 mglkg IV Methylprednisolone IV 
continuous 50 mg IV q 6h x 4 doses 
infusion 40 mg IV q 6h x 4 doses 
30 mg IV q 6h x 4 doses 
0.15 mg/kg po bid 20 mg IV 6h x 4 doses 
when taking po 20 mg IV q 12h x 2 
Prednisone 20 mg po qd 
Table 3. FK5061prednisone versus 
FK5061azathioprineiprednisone -
actuarial survival. 
n=199 n=198 n=397 
FKS06IPred FK506IAzalPred Overall 
(%) (%) (%) 
P9tient 
1-Yr 97 94 95 
2-Yrs 95 90 93 
Graft 
1-Yr 90 88 89 
2-Yrs 86 79 83 
p=NS 
Azathioprine 
3 mg/kg 
3 mglkg/d 
The Second RandomIzed 
TrIal· FK5061PrednIsone 
versus FK506lAzathioprinei 
Prednisone 
On the basis of these early results, a 
prospective, randomized open-label trial 
was begun in August 1991, comparing 2 
FK506-based regimens, with and without azathioprine 
(Table 2) (12,13,20,21). This trial was limited to adults 
undergoing kidney transplantation alone who consented 
to enter the trial. Children, patients receiving multiple 
concomitant organs, and patients who refused were ex-
cluded. The patient population was otherwise un selected, 
with 25% undergoing retransplantation, 1 SOk with a panel-
reactive antibody of over 40%, and 18% over age 60. 
Data on all 397 patients entered into the trial, which ended 
December 9, 1993, were recently presented (13). The 
overall 1- and 2-year actuarial patient surviva.1 rates were 
95% and 93%, respectively, and the overall 1- and 2-
year actuarial graft survival rates were 89% and 83%, 
respectively (Table 3, Fig. 1). No significant differences 
in patient or graft survival were seen between the double-
and triple-ch'ug regimens. 
8/1111 • 12/9183 . 
A multivariate analYSis was per-
formed to search for any factors predic-
tive of graft survival. The only signifi-
cant factor identified was the presence 
or absence of early graft function. The 
1- and 2-year actuarial graft survival 
- Patient SurvIval (n-395) 
-0- FK506+Pradniaone (n=198) 
-0- FK506+Azalhloprlne+Pradnisone (n-197) 
---- Graft Survival (n-397) 
--0-- FK506+Prednlsone (n-199) 
--0-- FK506+Azafhloprine+PradnIsone (n.198) 
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Figure 1. Actuarial patient and graft survival. 
rates for patients with immediate graft 
function were 94% and 89%, respec-
tively. However, in patients with initial 
nonfunction (defined either as lack of 
urine output within the first 48 hours or 
the need for dialysis within the first week 
after transplantation), the 1- and 2-year 
actuarial graft survival rates were 78% 
and 71%, respectively (Fig. 2 -
p<O.OOO1, relative risk 3.53, range 2.09-
5.91). Other factors, such as the pres-
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or race, antibody level, or primary/retrans-
plant status, were not associated with dif-
ferential outcomes (Table 4). ~ 
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nine clearance was 56±27 mVmin. The 
mean BUN was 32± 16 mgldl. There was 
no difference between the 2 groups. 
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Triple therapy was associated with 
less rejection than double therapy, both in 
patients treated with steroids (44% vs 
54%, p<O.05) and in those requiring 
antilymphocyte therapy (7% vs 14%, 
p<O.04). The incidence of other adverse 
events, such as early nonfunction, CMV, 
posttransplant Iymphoproliferative disorder 
(PTLD), and new-onset diabetes, was not 
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CD 20 - - ATN (n=138) 
A. 
-0- FK506+Prednisone (n=72) 
I···.· 
0 
--0- FK506+Azathioprine+Prednisone (n=66) 
0 6 12 18 24 30 36 
, 
L ,{c 
M()nths Posttra"splant 
" .. ' 
Figure 2. Graft survival in patients with and without 
initial graft function. 
influenced by the immunosuppressive group (Table 5). 
Forty-nine percent of the successfully transplanted 
patients were weaned off steroids. Thirty-five percent of 
the patients were off antihypertensive medications, and 
39% were on one medication only. The mean serum 
cholesterol was 195±49 mgldl. There were no differences 
between the 2 groups with respect to these parameters 
(Table 6). 
There was a high incidence of crossover, more from 
triple to double therapy (40%) than from double to triple 
therapy (17%). 
Table 4. FKS061prednisone versus 
FKS061azathioprineiprednisone 
selected subgroup analysis - actuarial 
graft survival (overall results). 
n=397 
1 Year 2 Years 
(%) (%) 
First cadaver 91 82 
Retransplant 83 80 
PRA >40% 87 85 
Recipient age ~60 yrs 87 75 
Black recipient 88 74 
No rejection 91 86 
Rejection 87 79 
NoATN8 94 89 
ATN 78 71 
Bp<0.OOO1 
This study showed that FK506 was an effective im-
munosuppressive agent in renal transplant patients. The 
1- and 2-year patient and graft survival rates were excel-
lent. It was possible to wean steroids in nearly half and 
antihypertensive medications in over one-third of the pa-
tients. The benefit of azathioprine was limited to a re-
duced incidence of rejection. No benefit was seen in 
terms of patient or graft survival. Given the need to dis-
continue azathioprine in 40% of the patients initially ran-
domized to triple therapy, it was felt that azathioprine as 
a third agent was of somewhat limited usefulness, and 
that perhaps one of the new azathioprine substitutes, such 
as mycophenolate mofetil (22), or brequinar (23), might 
Table S. FKS061prednisone versus 
FKS061azathioprineiprednisone adverse 
events. 
n=199 n=198 n::397 
FK5061Pred FK506IAzaiPred Overall 
(%) (%) (%) 
Rejection-steroids 54 44 49B 
Rejection- 14 7 10b 
OKT3IATG 
ATN 36 33 35 
CMV 15 16 16 
PTLD 2 1 1 
New-onset 12 9 10 
diabetes 
8p<O.05, bp<0.04 
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Table 6. FK506/prednisone versus FK506/ 
azathioprine/prednisone. 
n=199 n=198 n=397 
FK5061Pred FK5061AzalPred Overall 
Off steroids 50% 49% 49% 
Off antihypertensive 37% 34% 35% 
medications 
Serum cholesterol 192±52 199±45 195±49 
(mgldl) 
Only for functioning kidneys 
be worth evaluating. In the interim, a new ongoing ran-
domized trial of FK506-based therapy was started, com-
paring FK506/prednisone with FK506/prednisone and a 
one-week course of low-dose cyclophosphamide. 
Pediatric Transplantation 
Pediatric renal transplantation accounts for about 7% 
of the caseload at our institution. Because of the small 
number of cases and the nature of the patient popula-
tion, a randomized trial was not possible in our pediatric 
patients. In addition, results with CsA-based therapy in 
the pediatric patients were quite reasonable, with 100% 
and 97% 1- and 4-year actuarial patient survival rates, 
respectively, and 100% and 85% one- and 4-year actu-
arial graft survival rates, respectively (14,24). However. 
steroid withdrawal seemed particularly important in chil-
dren, and, by January 1994, 43 
Sixty-two percent of the children were weaned 
off steroids, and the associated effect on growth is 
shown in Table 8. Preadolescent children taken off 
steroids showed the most dramatic changes and 
actually went beyond catch-up growth to become 
slightly taller than average. 
The main adverse events are listed in Table 9. , 
The most important complications were viral infec-
tions. CMV was seen in 6 (14%) children. 5 of whom 
were seronegative reCipients of organs from 
seropositive donors. Intravenous ganciclovir was 
used successfully in all cases. EBV-associated 
PTLD was also seen in 5 (12%) cases. Immuno-
suppression was temporarily withdrawn, and anti-
viral therapy with ganciclovir or acyclovir was initi-
ated. In all cases, the PTLD resolved with good 
preservation of graft function. These complications 
probably represent a learning curve in the use of 
FK506 in children, as no new cases of PTLD have 
been seen in patients transplanted during the past 
21 months (as of October 1994). 
Table 7. Pediatric kidney transplanta-
tion under FK506 actuarial survival. 
Patient 
Graft 
1 Year 
100% 
98% 
n=43 
3 Years 
100% 
85% 
cases had been performed under 
FK506 therapy (25). Thirty-five per-
cent of these cases were 
retransplantations, many in children 
previously transplanted elsewhere. 
Twelve percent were in sensitized 
children. About half involved kid-
neys from living donors. 
100~.==.==.~.==~~========~~~~ 
L._., 
Results demonstrated 100% 
patient survival at one and 3 years 
(Table 7. Fig. 3). The one- and 3-
year actua.rial graft survival rates 
were 98% and 85%, respectively. 
The mean serum creatinine was 
1.2±O.6 mgldl, and the calculated 
creatinine clearance was 75±23 mV 
minl1.73 m2. The mean BUN was 
26±11 mg/dl. 
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- Patient Survival (n=43) 
- . - Graft Survival (n=43) 
.... 
c: 3 40 
...... CD ..... 
a. 
8 . ~!c:i30\~.~.. . 4~\ ·i4854 
·().,~sPQllJI:Jnsplal1t\) .......................  
.,-, ;"::';;x::::'<~A/:_,_-;':' . ' '-_ '.; :':-:':-;::::;i:i~:::'-:~i;:~;:>::: ;::._:'=. :_, '.,' '.,.: ":'C"'" ~:;~:,,:t{:,,:,{,:,:';::,:::·~ ;):::;':i/H 
Figure 3. Pediatric kidney transplantation under FK506 -
patient and graft survival. 
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Table 8. Growth after pediatric kidney transplantation under FK506. 
Z-Score (±SD) 
On Steroids Off Steroids 
<12 Years >12 Years ~12 Years >12 Years 
lime 
At transplant -1.9 (± 1.2) -3.0 (±1.1) -2.7 (±1.3) -2.3 (±2.6) 
3 months -1.7 &0.9) -2.9 &1.0) -1.5 (±0.7) -2.6 (±2.3) 
6 months -1.2 (±1.2) -2.7 (±1.1) -0.8 (±0.8) -2.1 (±2.5) 
1 year -0.4 (±1.1) -2.1 (±1.1) -0.02(± 1.7) -1.6 (±2.4) 
Most recent -0.42 (± 1.7) -2.0 (± 1.1) +O.92(±1.64) -1.4 (±2.3) 
Rejection occurred in 58% of patients; 7% required 
antilymphocyte therapy. All rejections were biopsy 
proven, and most occurred within the first 2 weeks after 
transplantation. 
The pediatric data demonstrated that excellent re-
sults can be obtained with FK506. In addition, the ability 
to wean the majority of children off of steroids has led to 
significant improvements in growth. 
Rescue 
The first use of FK506 in a renal transplant patient 
was in an attempt to rescue a chronically rejecting al-
lograft. This attempt failed (the patient went on to re-
ceive a second kidney under FK506 immunosuppression, 
which is still functioning well after 5 years), as did the 
next 5 attempts at rescue. Most of these early efforts 
were, in retrospect, poorly indicated, since the patients 
had a significant degree of scarring and/or chronic rejec-
tion. However, when rescue was attempted in patients 
with acute rejection who had failed CsA-based therapy, a 
number of allografts were salvaged. In both adults and 
children, 70-74% of patients were successfully rescued 
Table 9. Pediatric kidney transplanta-
tion under FK506 adverse events. 
n=43 
Rejection-Steroids 
OKT3IATG 
CMV 
PTLD 
ATN 
Temporary new-onset diabetes 
(Resolved in all cases) 
% 
58 
7 
14 
12 
7 
7 
(17,25,26). In patients with acute cellular rejection only, 
the success rate was 85%; in patients with both cellular 
and vascular rejection, the success rate was 65%; and in 
patients with acute cellular rejection and primary 
nonfunction of the allograft, the success rate was only 
40% (Table 10). Seventy-nine percent of the patients 
had received one or more courses of antilymphocyte 
therapy prior to being referred for rescue. Eighty-three 
percent had been transplanted elsewhere. Twenty-three 
percent of the patients arrived on dialysis, and half of 
them were successfully rescued. Twenty-one percent of 
successfully rescued patients were weaned off 
prednisone. Thus, FK506 has been useful in salvaging 
the majority of the patients with refractory acute rejection 
under conventional therapy. 
Bone Marrow Augmentation 
While this subsection has perhaps less to do spe-
cifically with FK506, it addresses an area of increasing 
importance in our clinical program. This project began 
with the observation that patients with extremely long graft 
survival (27-29 yrs) were found to be micro-chimeric with 
Table 10. FK506 rescue therapy in 
renal transplantation. 
n=77 
Successful rescue 
Overall 
Acute cellular rejection 
Cellular + vascular rejection 
Cellular rejection and 10 nonfunction 
On dialYSis 
Off steroids 
% 
74 
85 
65 
40 
50 
21 
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respect to the donor (27-30). Donor cells were found not 
only in the allograft but also in the peripheral blood, skin, 
and lymph nodes. Based on this observ~tion, we postu-
lated that infusion of donor bone marrow at the time of 
the transplant would augment chimerism in the recipient 
(18). The first combined, simultaneous kidney/bone 
marrow transplantation was performed on December 14, 
1992. An early report of the first 10 patients was pre-
sented in May 1994, at the American Society of Trans-
plant Surgeons (18). By September 27, 1994,30 kid-
ney/bone marrow transplantations had been performed. 
In 6 cases, pancreatic islets were also infused, and in 4 
cases, a pancreas transplant was also performed. Im-
munosuppression was with routine FK506 and steroids. 
The pancreas reCipients also received azathioprine, 2 mgt 
kg/day. All patients, except one, were undergoing their 
first transplantation. Radiation therapy, cytoreduction 
therapy, and induction antilymphocyte therapy were not 
given. Nineteen concurrent control patients, who did not 
. receive bone marrow (usually because of refusal of the 
donor's family to consent to vertebral body recovery), were 
also studied. Immunologic testing for chimerism was per-
formed prior to transplantation and at regular intervals 
posttransplantation. 
With a mean follow-up of 8.0±6.4 months, all study 
patients were alive, and 28 (93%) had functioning renal 
allografts (Table 11). Two kidneylbone marrow patients 
lost their allografts at 16 months after transplantation, 
one to noncompliance and one to rejection. The mean 
serum creatinine was 1.8±O.6 mg/dl, and the BUN was 
30±9 mg/dl. In the control patients, 18 (95%) patients 
were alive and 17 (89%) had functioning kidneys, with a 
mean serum creatinine of 2.3±~.3 mg/dl and a BUN of 
35±14 mg/dl. The incidence of early nonfunction, rejec-
tion, and CMV was comparable between study and con-
trol patients as shown in Table 11. Graft-versus-host dis-
ease was not seen in any study or control patient. 
The chimerism studies presented in May 1994 sug-
gested routine augmentation in all of the 9 evaluable pa-
tients, as documented either by flow cytometry, PCR, or 
fluorescent in-situ hybridization (for Y -chromosome analy-
sis). Chimerism was also noted in the control patients, 
but less often (3 or 5 evaluable patients) and to a lesser 
degree. Unpublished data on the larger group is similar, 
although the analYSis is still in progress. 
The conclusions drawn thus far from this experience 
are that kidneylbone marrow transplantation is straight-
forward and safe to perform, that it is associated with 
routine augmentation of chimerism, that it is not accom-
panied by graft-versus-host disease, that it yields excel-
lent patient and graft survival rates, and that it does not 
effect the early events after transplantation. More fol-
low-up data will be required to assess the long-term out-
come with bone marrow augmentation. 
Toxicity 
FK506 has the same toxicities that have been re-
ported with CsA, namely nephrotoxicity, neurotoxicity, and 
diabetogenicity (31-37). In general, these side effects 
are similar in degree and reversibility. The initial inci-
dence of new-onset diabetes has been as high as 18-
20% (13,37). However, much of this is reversible with 
reduction in both the FK506 and steroid dosages. The 
final incidence of new-onset insulin dependence, 6-10%, 
is about the same as that reported with CsA (38-40). 
CONCLUSIONS 
It is fair to say that FK506 has dramatically changed 
the outcome of renal transplantation at our institution. 
As a program committed to transplanting relatively high-
risk patients, we have previously reported one-year ac-
Table 11. Combined kidney/bone mar-
row transplantation. 
Kidney/Bone Marrow Control 
n=308 n=19 
% % 
Patient survival 100 95 
Graft survival 93 89 
Graft-vs-host disease 0 0 
Rejection 73b 58 
OKT3 13 11 
ATN 17 16 
CMV 13 16 
Off steroids 21 22 
8includes 6 kidney/isleVbone marrow 
4 kidney/pancreaslbone marrow 
tuarial graft survival rates of 74-80% (41,42). Our most 
recent data for adults have shown a 15% improvement 
in one- and 2-year actuarial graft survival, as well as an 
ability to discontinue steroids in half of the patients. In 
pediatriC patients, the use of FK50S has enabled us to 
achieve the same good primary outcomes and for the 
first time has allowed dramatic gains in height in the 
majority of patients weaned off prednisone. The ability 
to salvage over 70% of renal allografts failing conven-
tional immunosuppression has also proved to be an im-
portant advantage. Finally, the development of bone 
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marrow augmentation protocols has allowed the explo-
ration of chimerism in renal transplant patients, which may 
have important long-term implications. What FK50S has 
not eliminated are the problems of acute rejection and 
the persistence of antibody-mediated events. In addi-
tion, the same fundamental toxicities seen with GsA are 
present with FK50S. Unfortunately, a T-cell-active im-
munosuppressive agent without these side effects does 
not yet exist. Notwithstanding the problems noted above, 
in our hands FK506 represents a significant step forward 
in immunosuppression for kidney transplant patients. 
SUMMARY 
1. In an unselected adult renal transplant population, 3. FK50S has been used successfully in rescuing 70-
FK50S as the primary immunoslJppressive agent 74% of adult or pediatric renal transplant patients 
yielded one- and 2-year actuarial patient survival with an acute rejection that failed conventional 
rates of 95% and 93% and one- and 2-year actu- therapy. 
arial gra.ft survival rates of 89% and 83%, respec- 4. Kidneylbone marrow transplantation under FK506 
tively. Forty-nine percent of successfully trans- therapy has been successfully performed without 
planted patients were weaned off steroids. graft-versus-host disease and with routine aug-
2. In pediatric renal transplant patients, FKSOS has mentation of chimerism. 
been associated with 100% one- and 3-year actu- S. The side effects of FK50S included nephrotoxicity, 
arial patient survival rates and 98% and 85% one- neurotoxicity, and diabetogenicity; they were com-
and 3-year actuarial graft survival rates, respec- parable to those seen with GsA. 
tively. Sixty-two percent of successfully trans- S. FK506 is an important new addition to the immu-
planted patients were taken off prednisone, with nosuppressive armamentarium in renal transplant 
dramatic improvements in height. patients. 
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